Biologics
Skyhawk Therapeutics Reports Positive Nine Month Interim Data For SKY 0515 In Huntington’s Disease
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural hi...
January 29, 2026 | News
HKeyBio Introduces Translational Preclinical Strategy To Rethink Asthma And Allergy Drug Development
HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, announced a translational preclinical strategy, HKEY-AIRxTM1.0...
January 29, 2026 | News
Nuance Pharma’s Ohtuvayre NDA Accepted For Review In China For COPD Maintenance Treatment
Nuance Pharma announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA)...
January 28, 2026 | News
China Approves First Ever Therapy For Chronic Hepatitis D With Conditional Clearance For Libevitug
Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chroni...
January 28, 2026 | News
Innovent’s Tri Specific Antibody IBI3003 Secures US FDA Fast Track Designation In Relapsed Or Refractory Multiple Myeloma
Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment...
January 28, 2026 | Report
WuXi Biologics And HanchorBio Inc. Sign Strategic Collaboration To Advance Next Generation Fusion Biologics
WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a globa...
January 27, 2026 | News
Blau Farmacêutica Achieves End To End Development Of Pembrolizumab Biosimilar In Brazil
Blau Farmacêutica, a Brazilian pharmaceutical company listed on Brazilian Stock Market (B3) and a regional leader in hospital pharmaceuticals w...
January 27, 2026 | News
Ascletis Pharma Inc. Advances ASC30 Into U.S. Phase II Diabetes Study With Topline Data Expected In Q3 2026
-Topline data from the Phase II study for the treatment of diabetes are expected in the third quarter of 2026. -ASC30&n...
January 27, 2026 | News
Mabwell Doses First Patient In United States First In Human Trial Of Novel CDH17 Targeting ADC For Gastrointestinal Cancers
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed...
January 26, 2026 | News
Ellipses Pharma Limited In Licences First In Class B7H3 Targeted ADC From Innolake Biopharm Co. Ltd To Expand Global Oncology Pipeline
Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative programmes, announced th...
January 26, 2026 | News
Gene Solutions And Pangea Laboratory Partner To Advance US Clinical Validation Of Liquid Biopsy Tests
Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive ...
January 22, 2026 | News
Samsung Biologics Strengthens Long Term Growth Platform With Solid 2025 Financial Performance
Recorded Q4'25 revenue of KRW 1,286 billion and FY'25 revenue of KRW 4,557 billion Maintained momentum through consistent ...
January 22, 2026 | Company results
Alcami Expands Research Triangle Presence With Acquisition Of Durham Laboratory Facility
Alcami Corporation, a leading U.S.-based contract development and manufacturing organization (CDMO), has acquired a 37,000-square-foot facility at 4620 Cre...
January 21, 2026 | News
Alteogen Signs Exclusive Global Licensing Deal With GSK Subsidiary Tesaro For ALT B4
Alteogen Inc. (KOSDAQ: 196170) announced that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK...
January 21, 2026 | News
Most Read
- Innovations In Magnetic Resonance Imaging Introduced By United Imaging
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
